Mitsubishi UFJ Asset Management Co. Ltd. Acquires 163,244 Shares of Boston Scientific Corporation $BSX

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,111,069 shares of the medical equipment provider’s stock after purchasing an additional 163,244 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.21% of Boston Scientific worth $294,649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BSX. BOKF NA grew its holdings in Boston Scientific by 9.4% during the fourth quarter. BOKF NA now owns 30,691 shares of the medical equipment provider’s stock worth $2,926,000 after buying an additional 2,630 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Boston Scientific by 1.2% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 210,273 shares of the medical equipment provider’s stock worth $20,050,000 after acquiring an additional 2,517 shares during the last quarter. SBI Securities Co. Ltd. boosted its holdings in Boston Scientific by 4.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 4,055 shares of the medical equipment provider’s stock worth $387,000 after acquiring an additional 167 shares during the last quarter. Cresta Advisors Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter worth $33,000. Finally, Principal Financial Group Inc. grew its stake in shares of Boston Scientific by 2.1% in the 4th quarter. Principal Financial Group Inc. now owns 1,671,658 shares of the medical equipment provider’s stock worth $159,393,000 after acquiring an additional 34,420 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on BSX. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Evercore decreased their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Stifel Nicolaus reduced their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Robert W. Baird cut their price target on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. Finally, Jefferies Financial Group decreased their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Trading Down 1.5%

Shares of BSX stock opened at $55.98 on Wednesday. The stock has a market capitalization of $83.20 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 1.04 and a beta of 0.62. The company’s fifty day simple moving average is $66.69 and its two-hundred day simple moving average is $84.28. Boston Scientific Corporation has a 1 year low of $55.88 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company earned $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.